STATE OF THE INDUSTRY REPORT 2013

INSIGHTS AND INNOVATIONS FROM INDUSTRY LEADERS

MEDICAL DEVICE DAILY

THE DAILY MEDICAL TECHNOLOGY NEWS SOURCE
2013 STATE OF THE INDUSTRY REPORT

INSIGHTS AND INNOVATIONS FROM INDUSTRY LEADERS
Introduction
Med-tech innovation continues, but may be heading overseas ............................ 3

Industry Expert Panel
Innovators see both obstacles and opportunities as they assess the condition of medical innovation in the U.S. ................................. 9

NewCos on the Go
AirXpanders gets IDE to study AeroForm ............................................................ 19
Apollo Endosurgery raises $47.6M in Series B round .......................................... 21
New device may offer hope for ‘suicide headache’ .............................................. 23
Auxogyn aims to improve IVF outcomes with Eeva ........................................... 25
Avinger enrolls first U.S. patient in CONNECT II ................................................ 26
Bluegrass Vascular focuses on Surfacer ‘inside out’ catheter .............................. 28
New combat clamp device stops groin area bleeding ......................................... 30
CardioComm earns FDA clearance for OTC heart monitoring system .................. 32
Case Medical study uses fMRI to investigate dystonia ....................................... 34
HeartLight EAS lights the way for catheter ablation of AF .................................. 36
CellScope develops ear infection detection device via smart phone ...................... 38
CerebralRx enters market with vagus nerve stimulation device ............................ 40
CerviLenz offers screening tool for preterm birth risk ........................................... 42
ChromaGen’s lenses help aid color blind patients ................................................ 43
Clarimedix gains traction despite rough VC landscape ........................................ 45
CytoPherx gets $34 million in funding for kidney therapy .................................... 46
Dune to provide realtime analysis of cancer margin .............................................. 47
Ellipse uses ‘MAGEC’ for treatment of scoliosis .................................................. 49
Haldor launches ORLocate in U.S., for instrument tracking ................................. 51
ImageIQ’s partnership with NASA could boost profile ....................................... 53
Ivantis enrolls first patient in Hydrus Microstent study ....................................... 55
IVDiagnostics to monitor cancer treatment results with platform ......................... 57
iWalk robotic prosthetics to have ‘profound’ impact .......................................... 59
Kelyniam switches to med-tech industry, with skull implants ............................. 61
Simple device could solve complex problem of acid reflux ................................ 63
MindFrame ischemic stroke device successful in human procedure ..................... 65
NeuroNetics seeks to corner market on treating depression .................................. 66
NeuroSigma licenses UCLA patents to form NSVascular ................................... 68
Novasyte answers common device industry dilemma ........................................ 70
OvaScience secures $37M Series B funding ....................................................... 72
PhysioSonics sees nICP device as game-changer ................................................. 74
Previmed thrives while avoiding the traditional VC funding route ....................... 75
ReCor reports six month data for Paradise system .............................................. 77
Researchers fuse vessels together without sutures ............................................. 79
Heart tissue stimulation could lead to light-guided pacemakers ........................... 81
TSI set to launch Phantom MIS hip retractor system ........................................... 83
TransEnterix develops laparoscopic vessel sealer, stapler for Spider .................... 84
UCLA researchers develop hologram microscope device ................................. 85

Medical Device Daily™ State of the Industry
Table of Contents

Fear of unknown, not money, slows technology adoption ............................................. 87
InterVapor vows ‘no implant left behind’ in emphysema patients .............................. 89
VasoStitch set to solve PCI access/closure challenge ...................................................... 91
Velomedix gets IDE to evaluate rapid cooling system for AMI .................................. 93
World Micro sets sights on medical device market ......................................................... 94

By the Numbers

Conference Coverage
Medtronic CEO: ‘business model has to be adjusted’ ..................................................... 115
Private companies make their pitches to receptive audience ...................................... 117
Modified mosquitoes, robotic limbs, make Clinic’s Top 10 list for 2012 ....................... 120
Changing partnership models reflect new paths to business ..................................... 122
Leahy: Stakes for med-tech sector have never been higher ...................................... 124
Mexico streamlining its drug/device registration ......................................................... 126
Shuren promises to screen out ad hoc bar raising ....................................................... 128

Regulatory
Patent reform may prompt more filings, does little for pendency .............................. 133
Kerry’s message: Not ‘a choice between innovation and safety’ ................................. 135
Foster; ‘little incentive for cost-reducing technology’ ................................................... 136
Mobile application guidance a preliminary effort, says FDA ..................................... 137
FDA’s de novo tweak allows firms a parallel 510(k) filing .......................................... 138
FDA’s innovation blueprint relies on existing programs .............................................. 140
Patent reform will drive more global searches for prior art ....................................... 141
FDA inks IDE guidance for early feasibility studies .................................................... 143
FDA spells out new staged IDE approval in new draft guidance ................................ 144
CMS holds on pass-through payments for CY 2012 OPPS ......................................... 145
FDA formally adds a step to the device exemption process ...................................... 147
FDA updates 1988 guidance on substantial equivalence ........................................ 148
$595M user fee agreement will measure by total review times ................................. 149
Court rejects Prometheus patent citing danger to innovation ..................................... 150
Supreme Court vacates Myriad decision, remands case to CAFC ............................ 152
ESRD devices first entries to Innovation Pathway 2.0 .................................................. 154
CMS to cover TAVR via CED minus mandate for superiority ................................... 156
Device tax repeal bill clears House via vote of 270-146 ............................................. 157
Senate passed FDA user fee bill via a 92-4 vote ......................................................... 159
Roberts casts deciding vote to uphold Affordable Care Act ........................................ 161
CAFC judges exhibit no drift in respective views of Myriad ........................................ 163
## Table of Contents

**Industry Interviews**

Aspinall says diagnostics assure effective treatment ................................................. 167  
Ideas abound, but Belson follows a set of rules ......................................................... 171  
Coppola sees NovaSom, ASAA goal the same: serve patients ................................. 175  
Erdman optimistic about changing device industry .................................................. 179  
‘Nasty disease states’ creates opportunities for EKOS ............................................. 183  
Former pharma company Endo knee-deep in ‘health solutions’ ............................... 186  
Meyers heads up physician entrepreneurs group, SoPE .......................................... 189  
Nash sees healthcare mission as: improve care, cut costs ....................................... 193  
Avantis has ‘exciting opportunity’ in colon cancer detection ...................................... 197  
Founding values added to appeal of CEO post for Shimer ...................................... 200  
Topol urges patients to take control of their health data ......................................... 204  
GE healthymagination Fund invests on ‘mega-trends’ ............................................. 208  
PwC report: major opps eyed in healthcare sector .................................................... 210  
Yadav sees benefits of wireless sensing tech for HF patients ................................... 217  
Company Index ........................................................................................................... 223
The MDD Interview

Innovators see both obstacles and opportunities as they assess the condition of medical innovation in the U.S.

Interview by JIM STOMMEN, MDD Contributing Writer

As part of Med-Tech on a Mission: Strategies to Drive Innovation, a special edition of the MDD Interview was put together, with the focus on the state of medical innovation in the U.S.

A panel of entrepreneurs and innovators in the medical field shared their thoughts on a wide variety of issues related to where innovation is in this country today and where it seems to be headed in the future.

The participants include:

Thomas Fogarty, MD, PhD, president of Fogarty Research & Development (Portola Valley, California). A renowned cardiovascular surgeon, successful entrepreneur and investor, and an award-winning vintner, he is perhaps best known for inventing and patenting the Fogarty Balloon Catheter, a device which has revolutionized not only vascular surgery but the medical field overall.

He has been the founder/co-founder and chairman of the board of more than 33 business and research companies, all of which are based on devices designed and developed by Fogarty Engineering Inc. In 1993, Fogarty founded Three Arch Partners, a venture capital firm that invests in new healthcare companies.

Perry Genova, PhD, founder and CEO of medical device start-up firm Oncoscope (Durham, North Carolina), a maker of optical imaging systems for tissue sampling. A biomedical professional with expertise in medical and pharmaceutical product innovation and development. Previously, he previously served with GlaxoSmithKline and Kos Pharmaceuticals, and has also been involved in a number of successful start-up ventures, including Quill Medical (acquired by Angiotech in 2006) and IEP Pharmaceutical Devices (acquired by Kos Pharmaceuticals in 1999).

Josh Makower, MD, founder and CEO of ExploraMed Development (Mountain View, California), a medical device incubator. He also is a venture partner with New Enterprise Associates, where he supports the investing activity in the medical device arena, and is a consulting associate professor of medicine at Stanford, where he co-founded the university’s Biodesign Innovation Program.

Arlen Meyers, MD, president/CEO of the Society of Physician Entrepreneurs (SoPE; Denver). He also is professor of otolaryngology, dentistry and engineering at the University of Colorado Denver. The founder or co-founder of several companies, he is a consultant to life science, IT and investment firms.

Kevin Schulman, MD, professor of medicine in the Duke University School of Medicine (Durham, North Carolina), where he also serves as the director of the Center for Clinical and Genetic Economics and as an associate director of the Duke Clinical Research Institute. He holds a joint appointment as a professor of business administration in Duke University’s Fuqua School of Business, where he is the director of the Health Sector Management Program.

They chatted with MDD Contributing Writer Jim Stommen on
MDD: What's the state of medical device innovation in the U.S. today, and where do you see it headed?

Makower: I fundamentally believe that regardless of the downward pressure on healthcare cost, that Americans will continue to value their health above other needs and thus there is a future for medical innovation in the U.S. That said, the hurdles associated with reimbursement, certain government policies/taxes, regulatory challenges and access to capital will limit which projects can succeed and thus we must continue to evolve our thinking about which business models and technologies we can and should pursue. In all likelihood there will be a redistribution of focused effort as entrepreneurs adapt to these changes. Certainly government policies with respect to how new technologies are paid for and taxed could dramatically propel or depress innovation in our sector.

Schulman: That's a really challenging question. I think we're in transition between models. The need for new technology, for new medical devices, is great, but the customer in terms of the payer or the hospital is becoming increasingly challenging and that's putting a lot of pressure on the business model, at least in the U.S. And then we have an explosion of what we consider medical devices, from implantable devices to information technology systems to all kinds of new opportunities for sensors for remote monitoring. So I think the technology that enables us to do new things and exciting things is there and increasing in development, but the payers makes the reimbursement model and the business model around devices, and that's really challenging.

Genova: Personally, I believe the U.S. is still extremely innovative and creative as a nation and, more specifically, within the medical device sector. We have an abundance of people who are creative and understand the entrepreneurial model and the risks and rewards that are associated with it, and are willing and able to take these risks. However, I am concerned about the significant challenges ahead of us. The problem isn't fundamentally with our creative genius, but, rather, with the lack of a receptive environment on the back-end for that creativity. For innovation to thrive we must warmly embrace, on a national level, medical device innovation and reward innovation and innovators rather than hobbling them through regulatory complexity or by associating innovation with increased costs. I fear that the medical device innovation model in the U.S. may follow the outsourced manufacturing model for consumer products where we setup manufacturing somewhere else in the world and subsequently established engineering services to be proximal to the manufacturing centers. In a way, it's already begun. For some time now, medical device companies have launched products in Europe or Asia first and leveraged some of the revenue from those exercises to fund U.S. regulatory filings and commercialization. So, like the aforementioned outsourcing model, if we are focusing on commercializing outside of the U.S., it wouldn't be unusual to consider that innovation centers may follow.

Meyers: Overregulated, overtaxed and still mostly run by the combination of payers, industry and the government. Doctors and patients, the two most important ingredients in the innovation formula, are still on the margins.

Fogarty: It's an important issue, probably more important in this day and age than it has ever been. It's in trouble today, and right now it's not headed in a very good direction. An even more unfortunate thing is that many physicians really don't know that, and even fewer patients know that. But if you look at the facts, if you look at the reports being made at major medical meetings, probably a third of the information being presented is being presented by people from offshore. When I first entered this field 40 years ago, probably 90% of what was presented in the way of valuable new information came from the United States. Not anymore, and I don't think that is a welcome direction by any means. I think patients are not getting the care they should get, are not getting the care at the price they should get. Its multi-factorial, but a major reason is that medicine
NEW COs ON THE GO
AirXpanders gets IDE to study AeroForm

By AMANDA PEDERSEN
Medical Device Daily Senior Staff Writer

There has to be a better way.

That sentiment is what inspired the development of a new breast tissue expansion device for mastectomy patients undergoing breast reconstruction. The device, called AeroForm, was developed by AirXpanders (Palo Alto, California), which recently received an investigational device exemption from FDA to move forward with a clinical trial evaluating the technology.

The prospective, randomized, controlled, open-label pivotal study, XPAND (AirXpanders Patient Activated Controlled Tissue Expander System for Breast Reconstruction), will be conducted at multiple centers across the U.S. AirXpanders said the results will be used as the basis for its AeroForm 510(k) filing with the FDA.

Scott Dodson, president/CEO of AirXpanders, told Medical Device Daily that the current method for undergoing breast reconstruction following a mastectomy is a procedure during which the surgeon creates a space for a permanent implant. To do this, the surgeon makes a small incision into the woman’s pectoral muscle, inserts a silicone bag. Then, during weekly office visits, the surgeon inserts a needle through the skin into the tissue expander’s port to inject saline into the temporary implant. These weekly injections continue for upwards of four months, Dodson said.

So Daniel Jacobs, MD, a practicing plastic surgeon and one of the co-founders of AirXpanders, decided there had to be a better way.

What AirXpanders ended up coming up with was a breast tissue expansion device that would address the limitations of traditional saline expanders. The AeroForm tissue expander consists of a technologically advanced self-contained tissue expander and a small hand-held wireless remote control. Dodson said the system uses compressed carbon dioxide that is gradually released through a small internal valve, in place of invasive saline injections, to fill the expander. After a standard procedure to implant the expander, the patient is able to inflate the expander herself at home using the remote control, eliminating the need for weekly doctor visits and needle-based saline injections.

The patient can inflate the expander up to three times a day with a three-hour lock-out between doses. “We thought if we could expand the patient on a gradual daily basis we could get her there quicker,” Dodson told MDD.

The way the remote control part of the system works is that the patient waves it over the implant area to allow it to communicate with the implant.

“It’s like using a stud finder on the wall to find out where a stud is,” Dodson said. “This dose controller communicates when it is over the implant . . . once you’re in the sweet spot you simply press the button and immediately a 10 cc dose is delivered.”

He said the company recently completed its feasibility trial in Australia which showed that the implant was able to reach full expansion in about two weeks using the new device.

“This is a significant event in the fact that women want to get on to the recovery phase after they’ve gone through this horrible ordeal with cancer . . . we validated that we can help get them there quicker,” Dodson said. AirXpanders noted that the randomized, controlled clinical trial is designed to directly compare the outcomes of tissue expansion using the traditional saline expansion method to the investigational AeroForm, remote-controlled, needle-free tissue expander. Enrollment will continue until a total of 92 AeroForm devices have been implanted and 46 saline expanders have been implanted. Dodson said the company expects the trial to take six to eight months to complete.

Participating sites include hospitals in Atlanta, Boston, New York, St. Louis, San Diego and other cities across the U.S., the company noted.

“We’re very blessed to have some great sites on board with this study, we have not been told no by anyone, there has been great physician receptivity to this trial, which in my 25 years of working...
Apollo Endosurgery raises $47.6M in Series B round

By AMANDA PEDERSEN
*Medical Device Daily* Senior Staff Writer

Apollo Endosurgery (Austin, Texas) raised $47.6 million in its Series B financing round in February 2012. New investors Novo A/S, Remeditex Ventures, and CPMG joined existing investors PTV Sciences and H.I.G. BioVentures in the round. Proceeds were targeted for the commercial launch of the second generation OverStitch endoscopic suturing system and other Apollo endosurgery flexible surgical tools designed to allow surgeons and interventional endoscopists to perform numerous procedures without making incisions into the patient's skin.

As part of the financing, Jack Nielsen of Novo A/S, John Creecy of Remeditex and Kent McGaughey of CPMG will join Apollo's board.

"We are pleased to have this strong financial support from both our new and existing investors, which will enable a successful launch of the OverStitch platform and the broader adoption of flexible surgical approaches for numerous medical conditions," said President/CEO Dennis McWilliams. "This new financing will enhance Apollo's leadership position as an innovator and a driving force in advancing this new class of less invasive therapies."

McWilliams told *Medical Device Daily* that being able to raise such a significant round of funds in the current financial environment is a testament to Apollo's technology, the OverStitch, as well as the size of the opportunity the company is targeting. The company has been fortunate to have the continued support it has received from its existing investors, he noted.

"The past three years have been very challenging in the fundraising environment ... and that's constrained a lot of companies to build their businesses and grow," McWilliams said. "We put our heads down and focused on preserving our cash and continuing to hit the milestones, but we maintained our vision to develop the OverStitch." He added that the current financing is a testament to the size of market the company is going after.

"There are huge opportunities that have not been very well tapped," he said. This latest round, combined with Apollo's earlier round of $11.7 million, adds up to a total raised of $59.3 million.

Apollo's OverStitch platform combines the flexibility of endoscopy with the precision of surgical suturing, allowing physicians to access, manipulate and suture internal tissue without making incisions through the skin, the company says. The platform therefore allows physicians to develop less invasive options for the patient.

Ted Stephens, global marketing director at Apollo, told *MDD* that the second generation OverStitch is clinically very similar to the first generation of the device. "The second generation device was really designed to allow much easier, improved experience from the clinician’s perspective,” Stephens said. "It's much easier to use, it allows for more precision in placing sutures than the first generation device.” McWilliams added that Apollo built the OverStitch device to commercial scale, which is unique these days among medical device companies, he said. "Not many companies take that approach out of the gate, which is a testament to new times in medical devices,” McWilliams said.

With exit margins not being very solid in the industry over the last few years, McWilliams says companies need to build their businesses to have products built to scale from the start. With that in mind, he said Apollo has been built to be a self sustaining company because the traditional model of building a prototype device, running a clinical trial, and getting acquired is no longer as easy as it once was. "They really want to see traction in the market place and you really have to build your company like that from the start," he said, referring to companies looking at acquiring smaller startups.

Apollo also recently received FDA clearance for its SuMO platform designed to help surgeons remove large, flat pre-cancerous gastrointestinal lesions and polyps. The company now has 11 products cleared by FDA, McWilliams said. In general, this new class of flexible surgery procedures
Auxogyn aims to improve IVF outcomes with Eeva

By AMANDA PEDERSEN

Medical Device Daily™ Senior Staff Writer

The field of assisted reproduction is one that is highly subjective using today’s technology. The challenge embryologists are faced with during in vitro fertilization (IVF) procedures is to look at embryos under a microscope and decide, based on limited information, what the chances are that the embryo is viable enough to result in a successful pregnancy and decide the fate of that embryo.

“The ultimate objective of IVF procedures is to transfer one embryo that will result in one healthy baby,” Lissa Goldenstein, president/CEO of Auxogyn (Menlo Park, California), told Medical Device Daily.

The company’s first product, the Early Embryo Viability Assessment System (Eeva), was developed based on science and technology that started at Stanford University (California). Eeva brings the IVF field closer to its goal by providing solid data for the selection of embryo(s) to transfer, Goldenstein said. The noninvasive system is designed to provide IVF clinics and patients with objective information regarding embryo viability.

“We believe it will revolutionize the field of assisted reproduction because of the fact that it brings scientific rigor and objectivity to the selection of embryos,” Goldenstein said. “We believe that Eeva’s predictive capabilities will help guide the treatment path decisions for women pursuing IVF.”

Eeva's software is designed to automatically analyze embryo development against scientifically and clinically validated cell-division parameters. With Eeva’s quantitative data for each embryo’s potential development, according to Auxogyn.

The company was initially funded in May 2010 by Kleiner Perkins Caufield & Byers, TPG Biotech and Merck Serono Ventures.

Last week Auxogyn reported raising $18 million in a Series B financing round, which included new investor SR One.

“We believe that we’ve been able to attract a new high quality investor and secure participation from all existing investors due to the fact that Eeva brings scientific rigor and objectivity to the field of assisted reproduction, a field that is largely subjective today,” Goldenstein told MDD. “We believe the addition of SR One is a validation of the importance of our technology, the strong science behind Eeva, and also our ability to move this test quickly toward commercialization.”

The company has also recently completed a multicenter, 160-patient study to validate the safety and efficacy of Eeva, and plans to introduce the system to the European market later this year. The results of its clinical study are expected to support regulatory filings both in Europe and in the U.S.

“We are very excited to bring Eeva to the market, and we are absolutely committed to furthering research for women and their families pursuing assisted reproduction,” Goldenstein said.

In addition to Eeva, Auxogyn says it intends to develop other products to address infertility.

The company joins several others working on medical technology to address this need, including OvaScience (Cambridge, Massachusetts), INVO Bioscience (Beverly, Massachusetts), Incept BioSystems (Ann Arbor, Michigan), and Intimate Bridge to Conception (Ib2c; Pittsburgh), among others.

OvaScience, which was launched in 2011, recently completed a $37 million Series B financing. That company is developing a method of capturing mitochondria from a mother’s own ovarian stem cells and injecting them along with sperm into eggs for IVF.

Incept BioSystems has developed a device with the intention of enabling a continuous, refreshable culture microenvironment while using industry-standard IVF culture medium.

- **$400M - $699M**: 40%
- **$700M - $999M**: 12%
- **$1B - 2.9B**: 20%
- **more than $3B**: 28%


- **$100M-$399M**: 57%
- **greater than $800M**: 13%
- **$400M - $800M**: 9%
- **less than $100M**: 21%
- **greater than $800M**: 13%
- **$400M - $800M**: 9%
- **$100M-$399M**: 57%
- **less than $100M**: 21%

<table>
<thead>
<tr>
<th>Rank</th>
<th>Company</th>
<th>Value</th>
<th>Notes</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Bristol-Myers Squibb</td>
<td>$3.000B</td>
<td>increased its repurchase authorization</td>
<td>6/28/12</td>
</tr>
<tr>
<td>2</td>
<td>Baxter</td>
<td>$2.000B</td>
<td>authorized share repurchase program for up to 2 billion</td>
<td>7/26/12</td>
</tr>
<tr>
<td>3</td>
<td>Community Health Systems</td>
<td>$1.200B</td>
<td>aggregate principal amount</td>
<td>7/20/12</td>
</tr>
<tr>
<td>4</td>
<td>Health Care REIT</td>
<td>$1.100B</td>
<td>20.7 million shares in public offering</td>
<td>2/29/12</td>
</tr>
<tr>
<td>5</td>
<td>Cowen Healthcare Royalty Partners</td>
<td>$1.000B</td>
<td>Cowen Healthcare Royalty Partners II</td>
<td>1/6/12</td>
</tr>
<tr>
<td>6</td>
<td>Quest Diagnostics</td>
<td>$1.000B</td>
<td>increased share repurchase authorization</td>
<td>1/25/12</td>
</tr>
<tr>
<td>7</td>
<td>Community Health Systems</td>
<td>$1.000B</td>
<td>Senior notes due 2019</td>
<td>3/9/12</td>
</tr>
<tr>
<td>8</td>
<td>Hologic</td>
<td>$1.000B</td>
<td>private placement of 6.25% senior notes</td>
<td>7/20/12</td>
</tr>
<tr>
<td>9</td>
<td>Biomet</td>
<td>$1.000B</td>
<td>completed previously reported offering of senior notes due 2020</td>
<td>8/9/12</td>
</tr>
<tr>
<td>10</td>
<td>DaVita</td>
<td>$1.000B</td>
<td>offering to help with HealthCare Partners buy</td>
<td>8/15/12</td>
</tr>
<tr>
<td>11</td>
<td>LabCorp</td>
<td>$1.000B</td>
<td>priced offering of notes in two tranches</td>
<td>8/22/12</td>
</tr>
<tr>
<td>12</td>
<td>Healthcare REIT</td>
<td>$963M</td>
<td></td>
<td>2/23/12</td>
</tr>
<tr>
<td>13</td>
<td>Community Health Systems</td>
<td>$850M</td>
<td></td>
<td>4/6/12</td>
</tr>
<tr>
<td>14</td>
<td>Health Care REIT</td>
<td>$811M</td>
<td>total proceeds of stock sale</td>
<td>8/14/12</td>
</tr>
<tr>
<td>15</td>
<td>Stryker</td>
<td>$750M</td>
<td>offering of senior unsecured notes</td>
<td>9/15/11</td>
</tr>
<tr>
<td>16</td>
<td>Medtronic</td>
<td>$650M</td>
<td>offering of senior notes</td>
<td>3/15/12</td>
</tr>
<tr>
<td>17</td>
<td>Health Care REIT</td>
<td>$632.5M</td>
<td>public offering of stock</td>
<td>11/1/12</td>
</tr>
<tr>
<td>18</td>
<td>OrbiMed</td>
<td>$600M</td>
<td>creation of a new Investment Fund</td>
<td>9/1/12</td>
</tr>
<tr>
<td>19</td>
<td>Canaan Partners</td>
<td>$600M</td>
<td>mostly goes to tech investments</td>
<td>1/1/12</td>
</tr>
<tr>
<td>20</td>
<td>Health Care REIT</td>
<td>$600M</td>
<td>notes due 2019</td>
<td>3/29/12</td>
</tr>
<tr>
<td>21</td>
<td>Ventas</td>
<td>$600M</td>
<td>public offering of notes</td>
<td>4/16/12</td>
</tr>
<tr>
<td>22</td>
<td>Covidien</td>
<td>$600M</td>
<td>senior notes</td>
<td>5/23/12</td>
</tr>
<tr>
<td>23</td>
<td>Riverside Partners</td>
<td>$561M</td>
<td>committed capital</td>
<td>5/15/12</td>
</tr>
<tr>
<td>24</td>
<td>Biomet</td>
<td>$550M</td>
<td>aggregate principal amount</td>
<td>7/26/12</td>
</tr>
<tr>
<td>25</td>
<td>Perkin Elmer</td>
<td>$500M</td>
<td>offering of aggregate principal amount of 5% senior notes</td>
<td>10/24/11</td>
</tr>
</tbody>
</table>
CONFERENCE COVERAGE
Medtronic CEO: ‘business model has to be adjusted’

By AMANDA PEDERSEN
Medical Device Daily Senior Staff Writer

In an economy where people are more careful with their money than ever before, even the big guys in the industry have to take a disciplined approach with their business model. That was the take-home message from Medtronic (Minneapolis) CEO Omar Ishrak Monday at the 30th annual J.P. Morgan Healthcare Conference in San Francisco.

“The business model has to be adjusted without compromising the need for, and the desire for, higher standard of care,” Ishrak told his audience during a presentation that was also webcast. Ishrak said Medtronic has identified three key imperatives to improve its growth: improved execution; optimizing innovation; and globalization.

“We want a business that moves quickly and is agile,” he said in explaining the first of these three imperatives, improved execution.

Doing so requires a business alignment “so that everyone is moving in the same direction,” he added. Things like quarterly assessments and constant market connection are examples of this, Ishrak said, noting that he makes a point to meet in person with customers in the U.S. a few days a month. “Me and my management team want to stay in touch with customers,” he said.

In order to optimize innovation, Ishrak said the company will aim to improve its R&D spend and ‘optimize’ its capability. “This is not about going and getting engineers to work harder, nor is it about improving our technical capability,” he said. “It really is more about what we work on and how we work on it . . . working on things that don’t have an effective value proposition has to be de-focused. If there is no value proposition the innovation is not going to succeed.”

Doing this means providing economic value to customers, Ishrak said, adding that the company aims to develop products that either improves the hospital’s standard of care, increases procedure volumes, or improves quality of care so that the hospital’s quality metrics go up. “All of this will provide more revenue to a hospital,” he said.

Products that improve workflow for hospitals is another way the company strives to add value for its customers, Ishrak noted. “Reducing ICU stays . . . moving the shift of care from one type of physician to another or moving the care from the hospital to home,” are examples of innovation that improves hospital workflow, he said.

Finally, Ishrak noted, Medtronic will optimize product prices by providing better value for the same price.

“Customer economics is something that is going to be a screen for all of our new products,” Ishrak said.

Of course the company also recognizes the need to reach emerging markets for future growth. “Contrary to popular perception, our margins in emerging markets are actually as good if not better than . . . other markets,” Ishrak said.

Also, going forward, Ishrak told the audience that Medtronic will have to be more disciplined in its approach to acquisitions — as it will be for new product development and existing products — by first asking: Is it a growth market? Can Medtronic win in that market? And finally, can Medtronic add value to that market.

During another webcast presentation from the J.P. Morgan conference, the CEO of a considerably younger company, CareFusion (San Diego), offered his perspective on how companies like CareFusion can turn the current challenges in healthcare into opportunities.

“As all of you know, this is certainly not new news in this room today, this is certainly a challenging environment in healthcare markets in various parts of the globe,” CareFusion CEO Kieran Gallahue said. Specifically, he noted that “30% of U.S. hospitals are running at negative operating margins . . . they understand that they need to make some fundamental changes” including capturing efficiencies in their supply chain, primarily in the areas of pharmaceuticals and medical devices.

So while there is a lot of “doom and gloom” out there where healthcare is concerned, Gallahue
REGULATORY
Patent reform may prompt more filings, does little for pendency

By MARK McCARTY

Medical Device Daily Washington Editor

The U.S. Senate passed a long-awaited patent reform bill in September 2011, avoiding a showdown with the House over the lower chamber’s version of H.R. 1249 (the America Invents Act) by taking an up-or-down vote on the House version. President Obama signed the bill without delay as expected, but opinions diverged from there as to the value of the legislation for med-tech firms in the U.S.

Tony Shaw, counsel at the law firm of Arent Fox (Washington) and an adjunct professor of law at the Georgetown University Law Center (Washington), told Medical Device Daily that once the law goes into effect, inventors may conclude they “have to file preemptively even if [they] haven’t quite perfected the invention” because of the imposition of the first-to-file (FTF) paradigm embodied in the bill. Shaw also remarked that inventors in other nations are more savvy about the FTF approach and hence “we sort of put ourselves at a competitive disadvantage by adopting their system.”

On the other hand, JC Scott, senior executive VP for government affairs at the Advanced Medical Technology Association (AdvaMed; Washington), said in a statement e-mailed to Medical Device Daily that modernizing the patent process “is an important element of making sure that America’s medical device companies continue to be the world leaders.” Scott said FTF will “promote international harmonization and create efficiencies throughout the system.”

Not all the associations were as optimistic, however. Tom Novelli, VP for government affairs at the Medical Device Manufacturers Association (MDMA; Washington) said in a statement e-mailed to Medical Device Daily that the bill, “while not perfect, is a positive step towards updating the current patent system,” although Novelli expressed concern that the establishment of a new post-grant review process “may overburden PTO and provide a potential vehicle for abuse by some parties.”

The debate over the America Invents Act covered several amendments addressing issues such as business method patents, but the most important amendment in terms of the U.S. Patent and Trademark Office’s operations was offered by Sen. Tom Coburn (R-Oklahoma). Coburn’s amendment would have removed the patent fee diversion written into H.R. 1249, a feature that will send some patent fees to the general treasury fund, which would then be repatriated to PTO upon Congressional approval. The Senate voted 50-48 to table Coburn’s amendment.

Despite reassurances from many on Capitol Hill, Shaw echoed some of the widespread skepticism regarding Congress’s ability to keep its hands off PTO’s fees. “I don’t think anyone thinks Congress will behave itself” on this score, he said. “I think everyone recognizes the need to stop fee diversion, and it didn’t happen,” he shrugged.

Regarding the pendency/patent backlog problem, Shaw remarked, “you see articles by people who think throwing more money at PTO won’t solve the problem,” but he noted that the Board of Patent Appeals and Interferences at PTO is also working under a backlog. “There’s nothing in this legislation that’s going to address that,” he said.

Shaw seemed appreciative of the efforts by PTO’s management to streamline operations at the agency, but he said PTO director David Kappos may have “used all the tools in his toolkit to this point” to clear out the backlog. “I’m not sure how much more he can drive those numbers down,” and the new law may fuel ‘a huge surge of patent applications’ 18 months after passage.

As for the prior user rights issue, Shaw remarked that the intent is “to avoid snaring people who didn’t steal it from the inventor,” and “the reason we didn’t have that before is that we wanted to encourage people to file” so as to disseminate technological and methodological advances.

Among the things the bill does not do, Shaw said, is it does not affect eligible subject matter a la Prometheus v. Mayo. “There didn’t seem to be much push to do that,” he observed. He did not forecast much of an impact on lab-developed tests, however, at least not a negative effect.

“The big thing is that you develop some proprietary method of interpreting test results and you
INDUSTRY INTERVIEWS
Aspinall says diagnostics assure effective treatment
By JIM STOMMEN, MDD Contributing Writer

Mara Aspinall is president of Ventana Medical Systems (Tucson, Arizona), a maker of tissue-based cancer diagnostics and a member of the Roche Group. Prior to joining Ventana in September 2011, she was founder, president/CEO of On-Qity, a start-up diagnostics company focused on circulating tumor cell technology. Prior to that, Aspinall spent 12 years with Genzyme, where she held senior leadership roles as president of Genzyme Genetics and president of Genzyme Pharmaceuticals.

A frequent industry speaker, she has spearheaded industry-wide outreach initiatives to better educate the healthcare community and policymakers about the importance of diagnostics, genomics, and personalized medicine. Aspinall is a founder of DxInsights, a new organization focused on education regarding the importance of diagnostics in healthcare today and into the future.

MDD: What was the genesis of the DxInsights organization?
Aspinall: It started three years ago when a number of political and healthcare-related events occurred and the diagnostics community either did not get a full seat at the table or the industry was not fully understood by the key stakeholders. The diagnostics industry has become an order of magnitude more important over the last decade. This increased significance has happened as a result of new technologies that allow us to use diagnostics much more effectively, and the combination of diagnostics with specific therapeutics.

As a result of the coming together of the increasing importance of diagnostics and the increasing sophistication of diagnostics technology, we believed there was a need to set a foundational education around diagnostics across the broad healthcare industry. That was why we believed it was important to start a non-profit, independent, technology-agnostic, business model-agnostic organization that can provide that core education on diagnostics.

MDD: I would add as an outside observer, I too have thought that diagnostics has gotten short shrift from the policy perspective over the years, and I also agree with your view on how diagnostics has grown in importance over the past decade.
Aspinall: It is a great time to be in diagnostics. Many people believe they understand diagnostics today, but diagnostics has taken on a very different persona over the last decade. Diagnostics has moved from important but basic tests that analyze serum for single analytes to highly complex assays that identify and analyze genes, proteins and other markers from the smallest samples of tissue, blood and saliva.

Diagnostics now has the ability to do much more than just diagnose. It’s now about monitoring. It’s now about prediction. It’s now about prognosis. The dimensions for which diagnostics can add value has increased consistent with the changes and improvements in the technologies available.

MDD: The two words that really jumped out at me from that comment were “monitoring” and “prediction” or “prognosis.” What a different role for diagnostics today. Personally I think those have moved ahead of pure diagnosis in terms of the importance.
Aspinall: I don’t know if they have moved ahead, but they certainly have become at least as important.

MDD: All right, co-equals then.
Aspinall: Right. Many ask if diagnostics today is all about personalized medicine – I would argue that personalized medicine is critical and growing, but it’s still just a piece of the broader diagnostics industry. But if we are to make life-threatening diseases such as cancer into chronic diseases, it is no longer possible to say, we’re diagnosing them on Day One and you’re done – we must continue to monitor and assess patients through diagnostics.

AIDS is the best example. We don’t make one single diagnosis of AIDS and then treat the patient.
COMPANY INDEX
A
Abbott 122
Abbott Medical Optics 128
AcuFocus 109
Advanced Medical Technology Association 126, 128, 133, 149, 157, 160, 162
Aetna 103
Affymetrix 104
Agilent 103
Agile Therapeutics 110
AirXpanders 19
Alere 104
Allscripts 108
American Civil Liberties Union 163
American Glaucoma Society Annual Meeting 55
American Healthcare Investors 108
American Heart Association 81
American Intellectual Property Law Association 152
American Medical Systems 122
Amerigroup 103, 109
Ampel 53
AMS Group 40
AmSurg 105
Amtek 105
AngioDynamics 104
Apollo Endosurgery 21, 110
APS Healthcare 105
Ardian 77
Arent Fox 133
Aria Diagnostics 109
Arkansas Heart Hospital 26
Asahi Kasei 103
Ascend Health 103
Aspen 104
Association for the Advancement of Medical Instrumentation 148
Atrium Medical 110
Atrium Medical 103
Attends Healthcare 104
Autonomic Technologies 23
Auxogyn 25
Avantis Medical 197
Avinger 26

B
Bain Capital 103
Barrx Medical 104
Bausch + Lomb 107, 117
Baxa 104
Baxter 99, 101, 104, 106
Baxter International 104
Baylor Health System 156
BB&T Capital Market 108
BD 103
Bellevue 79
Biocartis 109
BioControl Medical 40
BioHorizons 109
Biotek 99, 101, 104, 106
Biosense Webster 122
BioServe Space Technologies 53
Biotechnology Industry Organization 151
Bluegrass Vascular Technologies 28
Boston Scientific 161
Boston Scientific 105
Bristol-Myers Squibb 99, 101, 106
Byrne Medical 105

C
Caliper Lifesciences 103
Cameron Health 105
Canaan Partners 99, 101, 106
Cantel Medical 105
Cantor & Nissel 43
Capital One Bank 109
Cardinal Health 116
Cardioangiologisches Centrum Bethanien 36
CardioComm Solutions 32
CardioFocus 36
CardioMEMS 219
CareFusion 105, 107, 115
Case Western Reserve University School of Medicine 34
Castlight Health 109
CellScope 38
CerebralRx 40
CerviLenz 42
Chinese University of Hong Kong 22
ChromaGen Vision 43
Cigna 103
Clarimedix 45
Clatterbridge Hospital 44
ClearCount Medical Solutions 52
Cleveland Clinic 53
Codman & Shurtleff Instrument business 105
Combat Medical Systems 30
Community Health Systems 99, 101, 106
Concentric Medical 105
ConforMIS 109
Cooper Companies 105
Corning 103
Coventry Health 103
Covidien 70, 77, 84, 99, 101, 104, 105, 106
<table>
<thead>
<tr>
<th>Company Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cowen Healthcare Royalty Partners 99, 101, 106</td>
</tr>
<tr>
<td>C.R. Bard 104, 105, 107</td>
</tr>
<tr>
<td>CreatiVasc Medical 155</td>
</tr>
<tr>
<td>Crescendo 109</td>
</tr>
<tr>
<td>Cynosure, Instrumentation Laboratory 183</td>
</tr>
<tr>
<td>CytoPhex 46</td>
</tr>
<tr>
<td><strong>D</strong></td>
</tr>
<tr>
<td>Dako 103</td>
</tr>
<tr>
<td>DaVita 99, 101, 103, 106</td>
</tr>
<tr>
<td>DePuy 104</td>
</tr>
<tr>
<td>Discovery Labs 110</td>
</tr>
<tr>
<td>DJO Global 108</td>
</tr>
<tr>
<td>Domtar 104</td>
</tr>
<tr>
<td>Duke University School of Medicine 9</td>
</tr>
<tr>
<td>Dune Medical Devices 47</td>
</tr>
<tr>
<td><strong>E</strong></td>
</tr>
<tr>
<td>Early Stage Partners, ONSET Ventures 46</td>
</tr>
<tr>
<td>eBioscience 104</td>
</tr>
<tr>
<td>Edison Pharmaceuticals 42</td>
</tr>
<tr>
<td>Edwards Lifesciences 70, 156, 161</td>
</tr>
<tr>
<td>EKOS 183</td>
</tr>
<tr>
<td>Ellipse Technologies 49</td>
</tr>
<tr>
<td>Emboline 92</td>
</tr>
<tr>
<td>Endo Health Solutions 186</td>
</tr>
<tr>
<td>Endo Pharmaceuticals 122</td>
</tr>
<tr>
<td>eReasearch 104</td>
</tr>
<tr>
<td>Ernest Health 104</td>
</tr>
<tr>
<td>eScreen 104</td>
</tr>
<tr>
<td>Estill Medical Technologies 31</td>
</tr>
<tr>
<td>Evolution1 108</td>
</tr>
<tr>
<td>Exact Sciences 109</td>
</tr>
<tr>
<td>Excel Venture Management 108</td>
</tr>
<tr>
<td>ExploraMed Development 9</td>
</tr>
<tr>
<td><strong>F</strong></td>
</tr>
<tr>
<td>Finnegan 163</td>
</tr>
<tr>
<td>Fogarty Research &amp; Development 9</td>
</tr>
<tr>
<td>Fresenious Medical Care 103</td>
</tr>
<tr>
<td>Fujifilm 103</td>
</tr>
<tr>
<td><strong>G</strong></td>
</tr>
<tr>
<td>GE Capital 108, 109</td>
</tr>
<tr>
<td>GE Healthcare 122, 208, 210</td>
</tr>
<tr>
<td>GE Medical Systems 183</td>
</tr>
<tr>
<td>Gen-Probe 103</td>
</tr>
<tr>
<td>Genstar Capital 104</td>
</tr>
<tr>
<td>Genzyme 167</td>
</tr>
<tr>
<td>Georgetown University Law Center 133</td>
</tr>
<tr>
<td><strong>H</strong></td>
</tr>
<tr>
<td>German Migraine and Headache Society 24</td>
</tr>
<tr>
<td>Getinge 104</td>
</tr>
<tr>
<td>GI Dynamics 109</td>
</tr>
<tr>
<td>Globus Medical 109</td>
</tr>
<tr>
<td>Haemonetics 103</td>
</tr>
<tr>
<td>Haldor Advanced Technologies 51</td>
</tr>
<tr>
<td>HealthCare Partners 103</td>
</tr>
<tr>
<td>Health Care REIT 99, 101, 106</td>
</tr>
<tr>
<td>Healthcare Trust of America 105, 108</td>
</tr>
<tr>
<td>HealthSpring 103</td>
</tr>
<tr>
<td>HealthStream 110</td>
</tr>
<tr>
<td>HeartFlow 109</td>
</tr>
<tr>
<td>Henry Schein 105, 107</td>
</tr>
<tr>
<td>Hill-Rom 104</td>
</tr>
<tr>
<td>Histogenics 110</td>
</tr>
<tr>
<td>Hologic 99, 101, 103, 106</td>
</tr>
<tr>
<td><strong>I</strong></td>
</tr>
<tr>
<td>Idaho Technologies 30</td>
</tr>
<tr>
<td>Illumina 109</td>
</tr>
<tr>
<td>ImageIQ 53</td>
</tr>
<tr>
<td>Incept BioSystems 25</td>
</tr>
<tr>
<td>Inspire Medical Systems 122</td>
</tr>
<tr>
<td>International Business Forum 123</td>
</tr>
<tr>
<td>International Headache Society 24</td>
</tr>
<tr>
<td>International Society for Heart and Lung Transplantation 88</td>
</tr>
<tr>
<td>Intersect Partners 65</td>
</tr>
<tr>
<td>Intuitive Surgical 171</td>
</tr>
<tr>
<td>Invibio 61</td>
</tr>
<tr>
<td>INVO Bioscience 25</td>
</tr>
<tr>
<td>IPC The Hospitalist Company 109</td>
</tr>
<tr>
<td>Ivantis 55</td>
</tr>
<tr>
<td>IVDiagnostics 57</td>
</tr>
<tr>
<td>iWalk 59</td>
</tr>
<tr>
<td><strong>J</strong></td>
</tr>
<tr>
<td>Jefferson School of Population Health 193</td>
</tr>
<tr>
<td>Johns Hopkins University 22</td>
</tr>
<tr>
<td>Johnson &amp; Johnson 45, 74, 80, 84, 186</td>
</tr>
<tr>
<td>Jones Day 163</td>
</tr>
<tr>
<td><strong>K</strong></td>
</tr>
<tr>
<td>Katherinen Hospital 65</td>
</tr>
<tr>
<td>Kelyniam 61</td>
</tr>
<tr>
<td>Kensey Nash 104</td>
</tr>
<tr>
<td>Kinetic Concepts 104</td>
</tr>
<tr>
<td><strong>L</strong></td>
</tr>
<tr>
<td>Medical Device Daily™ State of the Industry</td>
</tr>
</tbody>
</table>
LabCorp 99, 101, 105, 106
Lemhi Ventures 108
Lerner Research Institute 53
Levitronix 105
Liberty Dialysis Holdings 103
LifeScience Alley 123
LMA International 104
Lutonix 104

M
MannKind 109
Maquet Cardiovascular 103
Mayo Clinic 22
Medical College of Wisconsin 63
Medical Device Manufacturers Association 124, 133, 158, 162
Medical Properties Trust 104, 108
Medical University of South Carolina 22
Medivance 105
Mednax 107
Medrad 105
Medtox 105
Medtronic 74, 77, 99, 101, 106, 115, 122, 156
Medtronic Physio-Control 103
Memorial Sloan-Kettering Cancer Center 57
Metropolitan Health Networks 107
Mevion 110
Midwest Fund 46
MindFrame 65
M*Modal 103
Modular Surgical, RadGuard Medical 92
Molina Healthcare 108
Myriad Genetics 163

N
National HealthCare 109
National Health Investors 107
National Surgical Care 105
Navilyst Medical 104
NeoGuide Systems 92, 171
Neurionetics 66
NeuroPace 110
NeuroSigma 68
Newport Medical Instruments 105
Nora Therapeutics 186
NovaSom 175
Novasyte 70
NSVascular 68

O
Oak Hill 105
Omega Healthcare Investors 107
OncoScope 9
One Equity Partners 103
One Lambda 103
On-Q-ity 167
Optical Society 85
Optovue 118
OraSure Technologies 109
OrbiMed 101, 107
Oridion 104
Origo 105
Orthofix 105
Ospedale di Mirano 26
OvaScience 25, 72
Oxford Finance 107

P
Pall 103
Pathway Medical Technologies 105
Penumbra 117
PerkinElmer 101, 107
PerkinElmer 103
Pervasis Therapeutics 105
Phadia 103
PhotoMedex 110
Physio-Control 103
PhysioSonics 74
PreviMed 75
PricewaterhouseCoopers 212
PSS World Services 107, 108

Q
Quantum Medical Systems 183
Quest Diagnostics 99, 101, 106

R
Rainbow Medical 110
RBC Capital Markets 161
ReCor Medical 77
Reichert Technologies 105
Restoration Robotics 110
Rite Aid 107
Riverside Partners 101, 107
Rodman & Renshaw 110
Roper Industries 103
Rowa 105
Royal DSM 104

S
Santé 108